Wegovy approval opens the GLP-1 obesity market (2021)
The Food and Drug Administration approved semaglutide, sold as Wegovy, for chronic weight management. It was the first GLP-1 receptor agonist cleared specifically for obesity in the U.S.
Demand outstripped supply, and the drug became a cultural phenomenon.
It established a multi-billion-dollar market that pulled rival drugmakers into obesity research.
VK2735 would enter the market Wegovy created, competing on the same GLP-1 mechanism plus an added GIP target.
